Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis
NCT ID: NCT01252498
Last Updated: 2014-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
9 participants
OBSERVATIONAL
2010-12-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma
NCT02945878
Prevention of Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy
NCT03359187
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
NCT00790322
Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer
NCT01149642
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
NCT02542215
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The present study will measure the levels in saliva of the prostaglandins PGE2 and PGI2 before, during, immediately after, and several weeks after radiotherapy for head and neck cancer. These salivary levels will be correlated with clinical observation of mucositis and patient reporting of pain levels.
Improved understanding of the mechanism of mucositis may lead to the development of more effective targeted agents to prevent this problem.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Radiotherapy
Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving radiation therapy or chemoradiation therapy to the oropharynx
* Older than 18 years old
* ECOG performance status of 0-2
* Life expectancy greater than 2 months
* Signed informed consent
Exclusion Criteria
* Previous radiotherapy to the head and neck
* Other cancer diagnosis within the last 5 years except for non-melanoma skin cancer or non-metastatic prostate cancer
* Patient taking NSAIDs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vermont
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claire Verschraegen
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claire Verschraegen, MD
Role: PRINCIPAL_INVESTIGATOR
University of Vermont/Fletcher Allen Health Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fletcher Allen Health Care
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCC1005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.